RSS

NIO NIO Inc.

Mod: g&l
Last Post: 05/28/25
Followers: 1
Posts Today: 0
Views Today: 6966

NIO Stock Quote & Tools

$5.5900 ▲ +0.0000 (+0.00%) As of May 20, 4:00 PM EDT
Last5.5900
$ Chg0.0000
Open—
High—
Beta0.9748
Year High8.020
Market Cap14.01B
P/B Ratio23.49
EPS-0.98
Avg Vol (30d)33.57M
Volume13.62M
% Chg+0.00%
Prev Close5.5900
Low—
VWAP5.90936
Year Low3.340
Total Shares2.51B
Shares Out2.36B
Float2.14B
ExchangeNYSE
Consumer Discretionary Vehicles

NIO Stock Message Board Discussion

Top 10 Most Recent News Articles

Ideas Abu Dhabi Puts Water Innovation on Stage

Updated Category News Views 128

Water rarely gets the spotlight until a pipe fails, a harvest shrinks, or a city starts rationing. That is why the agenda around Ideas Abu Dhabi at the 2026 UN Water Conference deserves more than the usual polite nod given to conference programming. From 7 to 10 December in Abu Dhabi, this is shaping up as a public-facing attempt to connect a hard physical problem with...

Continue Reading
Sectra's RSNA AI Pitch Centers on Workflow, Not Hype

Updated Category News Views 121

Radiology has heard enough grand AI promises to fill a hospital basement, which makes Sectra's RSNA 2026 message refreshingly grounded. The Swedish imaging IT and cybersecurity company is putting its weight behind the unglamorous part of adoption: fitting AI into the daily diagnostic machinery without handing clinicians another awkward system to babysit. That is where...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 83

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
SK hynix Faces Fresh DRAM Collusion Risk for Investors

Updated Category News Views 24

A Memory Market Win Can Turn Sour Fast Nothing rattles a chip story quite like the word collusion showing up beside a judge’s ruling. SK hynix had been riding a powerful memory-market narrative, but investors got a blunt reminder on November 15, 2026: a proposed U.S. class action accusing SK hynix, Samsung Electronics, and Micron of restricting DRAM supply to raise...

Continue Reading
MegaRobo's Nearly $200 Million Bet on Learning Labs

Updated Category News Views 19

A lab robot that merely follows instructions is old news; a system that learns from the mess it makes is the expensive part. MegaRobo has raised nearly US$200 million to push toward that harder prize: infrastructure that links AI reasoning to actual experiments, instruments, automation and the results that come back. For investors watching AI for Science, this is more...

Continue Reading
Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 118

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading
JLL’s Facility Management Push Gets a Useful Nod From Frost

Updated Category News Views 27

A Building Breaks Down Long Before the Earnings Call Notices Facility management is the sort of business that gets ignored until an airport system fails, a data-center cooling unit balks, or a workforce cannot use the building it was told to return to. That is why Frost & Sullivan’s 2026 recognition of JLL deserves more than the usual award-season shrug. It points to an...

Continue Reading
Replit Bets on Trusted Creators to Sell AI Agents at Work

Updated Category News Views 47

Forty-five creators may sound like a marketing footnote, but Replit is aiming at a real enterprise bottleneck: people do not buy grand AI slogans; they buy proof that a messy internal problem can actually get fixed. Its newly launched Replit & Co. program puts business and technology creators in front of that problem, with product access, demonstrations and direct contact...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 147

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
Seeking Alpha Premium Review: Data Meets Human Judgment

Updated Category News Views 148

A spreadsheet can spot a cracked windshield, but it cannot tell you where the truck is headed. That is the useful, slightly irritating truth behind Seeking Alpha Premium’s 2026 pitch: it puts an enormous amount of stock-research machinery in one place, yet the investor still has to do the driving. Software Experts has highlighted the service in its review of...

Continue Reading

Top 5 Most Recently Viewed Articles

Hepsiburada's Impressive Q3 2025 Performance Review

Updated Category News Views 281

Hepsiburada Reports Significant Gains in Q3 2025 Hepsiburada, officially known as D-MARKET Electronic Services & Trading (NASDAQ: HEPS), has unveiled robust financial results for the third quarter of 2025. The Turkish e-commerce giant reported an impressive increase in gross merchandise value (GMV) and revenue, highlighting the company's operational resilience in a...

Continue Reading
Fulcrum Therapeutics Faces Challenges Amid Sickle Cell Trials

Updated Category News Views 212

Market Moves and Stock Reactions So, let’s get straight to the meat of it. Fulcrum Therapeutics Inc. (NASDAQ:FULC) took a nosedive recently—down about 10%—right after they dropped the latest news on their Phase 1b trial for pociredir aimed at treating sickle cell disease. Stock fell to around $9.80, and honestly, if you're still holding shares, well, it's time to...

Continue Reading
SBM Offshore's Share Repurchase Program Insights and Updates

Updated Category News Views 215

Overview of SBM Offshore’s Share Repurchase Program SBM Offshore has recently conducted a significant share repurchase program amounting to EUR141 million (approximately US$150 million). This initiative began on April 24, 2025, and aims to reduce share capital while also supporting management and employee share programs. The program has been designed to both enhance...

Continue Reading
Plymouth Industrial REIT Responds to Acquisition Proposal

Updated Category News Views 212

Plymouth Industrial REIT Receives Unsolicited Acquisition Proposal Plymouth Industrial REIT, Inc. (NYSE: PLYM), a leader in the industrial real estate sector, recently attracted attention with an unsolicited and non-binding acquisition proposal. This proposal comes from Sixth Street Partners, LLC, and suggests a price of $24.10 per share for all outstanding shares of the...

Continue Reading
Middlefield Canadian Income PCC AGM Results Breakdown

Updated Category News Views 230

Overview of the AGM Results for Middlefield Canadian Income PCC Middlefield Canadian Income PCC (the "Company") and Middlefield Canadian Income - GBP PC (the "Cell") have recently concluded their annual general meeting, a significant event that spotlighted the Company's journey and future direction. Conducted with transparency and diligence, this meeting has underscored...

Continue Reading